Sickle Cell Disease Treatment Market Analysis

Sickle Cell Disease Treatment Market Analysis

To get key market trends

  Download Free Sample

Based on treatment modality, the global sickle cell disease treatment market is subdivided into blood transfusion, pharmacotherapy, and bone marrow transplant. Pharmacotherapy is further subdivided on the basis of drug type and route of administration. On the basis of drug type, pharmacotherapy is classified into Hydroxyurea, Oxybryta, Adakveo, Endari, and other pharmacotherapies.
 

The blood transfusion segment dominated the market in 2022 with a revenue share of 65.1%. For sickle cell disease, blood transfusion has been considered the most effective treatment option to treat severe symptoms like strokes. Due to the rising number of episodes of stroke in sickle cell anemia patients, the demand for blood transfusion treatment has increased. Moreover, during the forecast period, the pharmacotherapy segment is anticipated to grow at a significant CAGR. Factors such as the introduction of new branded pharmacotherapy drugs, a strong pipeline, and increasing R&D activities fuel the market demand.
 

On the basis of drug type, the market for pharmacotherapy is subdivided into Hydroxyurea, Oxybryta, Adakveo, Endari, and other pharmacotherapies. Hydroxyurea segment dominated the market in 2022 and is expected to display significant growth. Hydroxyurea is an ideal drug for sickle cell disease patients by reducing the pain crisis and need for blood transfusion, due to which the demand and utilization of hydroxyurea are rising.
 

On the basis of route of administration, the market for pharmacotherapy is subdivided into oral and parenteral. The oral segment held the highest market share in 2022 owing to high adoption, non-invasiveness, patient compliance, and convenience. Many of the pharmacotherapy drugs are administered orally; for instance, hydroxyurea or Endari are available in tablet form.
 

Based on disease type, the global sickle cell disease treatment market is classified into sickle cell anemia, hemoglobin sickle C disease (HbSC), and other disease types. The sickle cell anemia segment accounted for the largest share in 2022 due to the high prevalence of sickle cell anemia. It is the most common and severe form of sickle cell disease, and the increasing complications associated with sickle cell anemia such as hemolysis or vaso-occlusive crises, are factors contributing to the growth of this segment.
 

Based on end-user, the global sickle cell disease treatment market is subdivided into hospitals, specialty clinics, and other end-users. Among the end-user segments, the hospital segment held the highest revenue share of the market in 2022. The increasing prevalence of sickle cell disease, development of new therapies for treating sickle cell disease, increasing government initiatives in launching the new drugs and increased number of admissions for sickle cell disease in hospitals accelerated the growth of this segment.
 

In 2022, the North America held the highest revenue in this market, owing to an increased prevalence of sickle cell diseases, increasing investments for R&D for developing new drugs for treating sickle cell disease, presence of key players, and well-developed healthcare infrastructure. During the forecast period, Asia Pacific segment is anticipated to witness significant growth due to the increasing prevalence of sickle cell disease and increased government initiatives and fundings.
 

In North America segment, U.S. accounted for the highest market share in 2022 due to the better access to treatment options, strong promising pipeline drugs, increasing number of product launches, acquisitions and increasing awareness and demand for sickle cell disease treatment.